Civallero M - Search Results

1

Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination.

Cosenza M, Civallero M, Marcheselli L, Sacchi S, Pozzi S. Cosenza M, et al. Among authors: civallero m. Apoptosis. 2020 Jun;25(5-6):370-387. doi: 10.1007/s10495-020-01607-3. Apoptosis. 2020. PMID: 32394008 Free PMC article.

2

Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts.

Cosenza M, Civallero M, Sacchi S, Marcheselli R, Pozzi S. Cosenza M, et al. Among authors: civallero m. Leuk Lymphoma. 2005 Feb;46(2):257-63. doi: 10.1080/10428190400014991. Leuk Lymphoma. 2005. PMID: 15621810

3

The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines.

Neri A, Marmiroli S, Tassone P, Lombardi L, Nobili L, Verdelli D, Civallero M, Cosenza M, Bertacchini J, Federico M, De Pol A, Deliliers GL, Sacchi S. Neri A, et al. Among authors: civallero m. Leuk Lymphoma. 2008 Jul;49(7):1374-83. doi: 10.1080/10428190802078289. Leuk Lymphoma. 2008. PMID: 18452078

4

Molecular targeting of the PKC-beta inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression.

Verdelli D, Nobili L, Todoerti K, Intini D, Cosenza M, Civallero M, Bertacchini J, Deliliers GL, Sacchi S, Lombardi L, Neri A. Verdelli D, et al. Among authors: civallero m. Hematol Oncol. 2009 Mar;27(1):23-30. doi: 10.1002/hon.875. Hematol Oncol. 2009. PMID: 18759374

5

Effects of enzastaurin, alone or in combination, on signaling pathway controlling growth and survival of B-cell lymphoma cell lines.

Civallero M, Cosenza M, Grisendi G, Marcheselli L, Todoerti K, Sacchi S. Civallero M, et al. Leuk Lymphoma. 2010 Apr;51(4):671-9. doi: 10.3109/10428191003637290. Leuk Lymphoma. 2010. PMID: 20218811

6

Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma.

Civallero M, Cosenza M, Bari A, Sacchi S. Civallero M, et al. Expert Opin Investig Drugs. 2011 Aug;20(8):1029-31. doi: 10.1517/13543784.2011.594793. Epub 2011 Jun 25. Expert Opin Investig Drugs. 2011. PMID: 21702717 No abstract available.

7

Genomic profiling of enzastaurin-treated B cell lymphoma RL cells.

Civallero M, Cosenza M, Neri A, Bari A. Civallero M, et al. Hematol Oncol. 2011 Sep;29(3):154-6. doi: 10.1002/hon.974. Epub 2010 Oct 27. Hematol Oncol. 2011. PMID: 21922509 No abstract available.

8

Combination of low doses of enzastaurin and lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines.

Cosenza M, Civallero M, Grisendi G, Marcheselli L, Roat E, Bari A, Sacchi S. Cosenza M, et al. Among authors: civallero m. Ann Hematol. 2012 Oct;91(10):1613-22. doi: 10.1007/s00277-012-1490-6. Epub 2012 May 24. Ann Hematol. 2012. PMID: 22623160

9

NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy.

Civallero M, Cosenza M, Marcheselli L, Pozzi S, Sacchi S. Civallero M, et al. Expert Opin Investig Drugs. 2012 Nov;21(11):1597-606. doi: 10.1517/13543784.2012.719871. Epub 2012 Aug 25. Expert Opin Investig Drugs. 2012. PMID: 22920938

10

The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines.

Cosenza M, Civallero M, Pozzi S, Marcheselli L, Bari A, Sacchi S. Cosenza M, et al. Among authors: civallero m. Hematol Oncol. 2015 Dec;33(4):166-75. doi: 10.1002/hon.2179. Epub 2014 Nov 13. Hematol Oncol. 2015. PMID: 25394177

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

40 results

Search Page

Filters